Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Fuji
Queensland Health
Cantor Fitzgerald
Chubb
McKinsey
Teva
US Army
Cerilliant

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,333,044

« Back to Dashboard

Which drugs does patent 6,333,044 protect, and when does it expire?

Patent 6,333,044 protects SPRIX and is included in one NDA.

This patent has nine patent family members in eight countries.
Summary for Patent: 6,333,044
Title: Therapeutic compositions for intranasal administration which include KETOROLAC.RTM.
Abstract:An analgesic/anti-inflammatory pharmaceutical dosage form which comprises an effective amount of an active ingredient selected from the group consisting of racemic 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, optically active forms thereof and pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable excipient or diluent, said dosage form being an intranasally administrable dosage form.
Inventor(s): Santus; Giancarlo (Milan, IT), Bottoni; Giuseppe (Bergamo, IT), Bilato; Ettore (Padua, IT)
Assignee: Recordati, S.A. Chemical and Pharmaceutical Company (Chiasso, CH)
Application Number:08/383,707
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Composition; Formulation; Use; Delivery;

Drugs Protected by US Patent 6,333,044

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Egalet Us Inc SPRIX ketorolac tromethamine SPRAY, METERED;NASAL 022382-001 May 14, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,333,044

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
ItalyMI91A2024Jul 22, 1991

Non-Orange Book US Patents Family Members for Patent 6,333,044

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,267,827 Therapeutic compositions for intranasal administration which include KETOROLAC ➤ Try a Free Trial
7,476,689 Therapeutic compositions for intranasal administration which include KETOROLAC ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,333,044

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Italy MI912024 ➤ Try a Free Trial
Italy 1250691 ➤ Try a Free Trial
Denmark 0524587 ➤ Try a Free Trial
European Patent Office 0524587 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Moodys
Colorcon
Covington
Fuji
Cipla
QuintilesIMS
Dow
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.